Copyright Reports & Markets. All rights reserved.

Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Nonselective MAO-Ainhibitors
    • 1.2.3 Selective MAO-B inhibitors
    • 1.2.4 Nonselective MAO-B inhibitors
  • 1.3 Market by Application
    • 1.3.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application: 2020 VS 2026
    • 1.3.2 Depression Treatment
    • 1.3.3 Parkinson's Disease Treatment
    • 1.3.4 Other Therapy
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Perspective (2015-2026)
  • 2.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Growth Trends by Regions
    • 2.2.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Historic Market Share by Regions (2015-2020)
    • 2.2.3 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Players by Market Size
    • 3.1.1 Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Players by Revenue (2015-2020)
    • 3.1.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Players (2015-2020)
  • 3.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue
  • 3.4 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Concentration Ratio
    • 3.4.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue in 2019
  • 3.5 Key Players Reversible Inhibitors of Monoamine (RIMA) Antidepressants Area Served
  • 3.6 Key Players Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Solution and Service
  • 3.7 Date of Enter into Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Breakdown Data by Type (2015-2026)

  • 4.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Historic Market Size by Type (2015-2020)
  • 4.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Type (2021-2026)

5 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Breakdown Data by Application (2015-2026)

  • 5.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Historic Market Size by Application (2015-2020)
  • 5.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2015-2026)
  • 6.2 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2015-2020)
  • 6.3 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2015-2020)
  • 6.4 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2015-2026)
  • 7.2 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2015-2020)
  • 7.3 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2015-2020)
  • 7.4 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2015-2026)
  • 8.2 China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2015-2020)
  • 8.3 China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2015-2020)
  • 8.4 China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2015-2026)
  • 9.2 Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2015-2020)
  • 9.3 Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2015-2020)
  • 9.4 Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2015-2026)
  • 10.2 Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

  • 11.1 Alkermes Plc
    • 11.1.1 Alkermes Plc Company Details
    • 11.1.2 Alkermes Plc Business Overview
    • 11.1.3 Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.1.4 Alkermes Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020))
    • 11.1.5 Alkermes Plc Recent Development
  • 11.2 Allergan Plc
    • 11.2.1 Allergan Plc Company Details
    • 11.2.2 Allergan Plc Business Overview
    • 11.2.3 Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.2.4 Allergan Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.2.5 Allergan Plc Recent Development
  • 11.3 Bristol Myers Squibb Co.
    • 11.3.1 Bristol Myers Squibb Co. Company Details
    • 11.3.2 Bristol Myers Squibb Co. Business Overview
    • 11.3.3 Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.3.4 Bristol Myers Squibb Co. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.3.5 Bristol Myers Squibb Co. Recent Development
  • 11.4 Eli Lilly& Co.
    • 11.4.1 Eli Lilly& Co. Company Details
    • 11.4.2 Eli Lilly& Co. Business Overview
    • 11.4.3 Eli Lilly& Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.4.4 Eli Lilly& Co. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.4.5 Eli Lilly& Co. Recent Development
  • 11.5 GlaxoSmithKline Plc
    • 11.5.1 GlaxoSmithKline Plc Company Details
    • 11.5.2 GlaxoSmithKline Plc Business Overview
    • 11.5.3 GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.5.4 GlaxoSmithKline Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.5.5 GlaxoSmithKline Plc Recent Development
  • 11.6 H. Lundbeck
    • 11.6.1 H. Lundbeck Company Details
    • 11.6.2 H. Lundbeck Business Overview
    • 11.6.3 H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.6.4 H. Lundbeck Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.6.5 H. Lundbeck Recent Development
  • 11.7 Merck
    • 11.7.1 Merck Company Details
    • 11.7.2 Merck Business Overview
    • 11.7.3 Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.7.4 Merck Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.7.5 Merck Recent Development
  • 11.8 Pfizer
    • 11.8.1 Pfizer Company Details
    • 11.8.2 Pfizer Business Overview
    • 11.8.3 Pfizer Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.8.4 Pfizer Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.8.5 Pfizer Recent Development
  • 11.9 Teva Pharmaceutical Industries Ltd.
    • 11.9.1 Teva Pharmaceutical Industries Ltd. Company Details
    • 11.9.2 Teva Pharmaceutical Industries Ltd. Business Overview
    • 11.9.3 Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.9.4 Teva Pharmaceutical Industries Ltd. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.9.5 Teva Pharmaceutical Industries Ltd. Recent Development
  • 11.10 Takeda Pharmaceutical Co. Ltd.
    • 11.10.1 Takeda Pharmaceutical Co. Ltd. Company Details
    • 11.10.2 Takeda Pharmaceutical Co. Ltd. Business Overview
    • 11.10.3 Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
    • 11.10.4 Takeda Pharmaceutical Co. Ltd. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2015-2020)
    • 11.10.5 Takeda Pharmaceutical Co. Ltd. Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Reversible Inhibitors of Monoamine (RIMA) Antidepressants market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Reversible Inhibitors of Monoamine (RIMA) Antidepressants market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Nonselective MAO-Ainhibitors
    Selective MAO-B inhibitors
    Nonselective MAO-B inhibitors

    Market segment by Application, split into
    Depression Treatment
    Parkinson's Disease Treatment
    Other Therapy

    Based on regional and country-level analysis, the Reversible Inhibitors of Monoamine (RIMA) Antidepressants market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Reversible Inhibitors of Monoamine (RIMA) Antidepressants market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Alkermes Plc
    Allergan Plc
    Bristol Myers Squibb Co.
    Eli Lilly& Co.
    GlaxoSmithKline Plc
    H. Lundbeck
    Merck
    Pfizer
    Teva Pharmaceutical Industries Ltd.
    Buy now